skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Measurement of bone turnover in prostate cancer patients receiving intermittent androgen suppression therapy

Original Research

(1997) Views  (421) Full article downloads

Authors:

Gerhard Theyer, Stefan Holub, Ulrike Olszewski, et al

Published Date September 2010 Volume 2010:2 Pages 155 - 159
DOI: http://dx.doi.org/10.2147/RRU.S13046

Gerhard Theyer1, Stefan Holub2, Ulrike Olszewski3, Gerhard Hamilton3

1Hospital Kittsee, Kittsee, Burgenland, Austria; 2Department of Urology, Wilhelminenspital, Vienna, Austria; 3Ludwig Boltzmann Society, Vienna, Austria

Purpose: Reports on clinical measurements of bone mineral density (BMD) in prostate cancer patients undergoing intermittent androgen suppression therapy (IAS) that allows for hormonal recovery between treatment cycles indicate decreased osteoporosis compared to continuous androgen suppression therapy (CAS). In the present study the effect of IAS on bone metabolism by determinations of CrossLaps, a biochemical marker of collagen degradation, were examined.

Method: In total 100 IAS treatment cycles of 75 patients with prostate cancer stages ≥ pT2 were studied. Clinical data and monthly laboratory tests (testosterone, prostate-specific antigen; PSA) of these patients were monitored together with measurements of C-terminal telopeptide collagen fragments using CrossLaps® ELISA assays.

Results: During phases of androgen suppression (AS) lasting for 9 months serum testosterone (<1 ng/mL) and PSA (<2 ng/mL) levels were reversibly reduced, indicating partial growth arrest and apoptotic regression of the prostatic tumors. Serum CrossLaps concentrations peaked at the last 2 months of the AS phases (0.91 ± 0.25 µg/L; mean ± SEM) and were reduced below initial values (0.21 ± 0.43 versus baseline of 0.43 ± 0.06 µg/L) during therapy cessation periods until tumor progression-related increases.

Conclusion: Measurements of the serum concentration of CrossLaps in prostate cancer patients receiving IAS indicated that treatment cessation phases rapidly reversed increased bone degradation associated with AS phases, in strong agreement with the clinical observations reporting reduced loss of BMD in IAS when compared to CAS. In terms of clinical outcomes, IAS seems to be as effective as CAS while showing reduced side effects, as demonstrated here by the reduction of androgen-induced bone matrix degradation.

Keywords: intermittent androgen suppression, prostate cancer, prostate-specific antigen, testosterone, bone turnover, CrossLaps






 

Other articles by Professor Gerald Hamilton



Readers of this article also read:

Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm: Comparison with high cardiovascular risk population
Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
Refinement of rigid-body protein–protein docking using backbone and side-chain minimization with a coarse-grained model
ABO and rhesus blood group distribution in Kurds
Comparison of the effects of the oral anticancer platinum(IV) complexes oxoplatin and metabolite cis-diammine-tetrachlorido-platinum(IV) on global gene expression of NCI-H526 cells
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
Editorial
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Corrigendum
Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?